Thomas Conlon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Conlon has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Nicolas Touzet
Department of Environmental Science; Centre of Environmental Research, Sustainability, and Innovation, Atlantic Technological University, Sligo, Ireland
5 shared publicationsGiorgia Adamo
Cell-Tech HUB and Institute for Research and Biomedical Innovation (IRIB), National Research Council of Italy (CNR), Palermo 90146, Italy
2 shared publicationsAdrian Timmers
Applied Genetic Technologies Corporation (AGTC), Alachua, FL
1 shared publication- Alok K. Sharma
Labcorp, Madison, Wisconsin, USA
1 shared publication Ana Mateos-Maroto
Max Planck Institute for Polymer Research, Ackermannweg 10, Mainz 55128, Germany
1 shared publication- Angela Patti
Cell-Tech HUB and Institute of Biophysics (IBF) - National Research Council of Italy (CNR), Palermo 90146, Italy
1 shared publication
Latest Publications
- Open Access
- 18 July 2025
- Published by Elsevier in Journal of Biotechnology
- Vol. 406, 236-243
Optimizing sustainable production of high-quality microalgae-derived extracellular vesicles through batch-refeed perfusion cultivation
- 18 July 2025
- Published by Elsevier in Journal of Biotechnology
- Vol. 406, 236-243
Open AccessOptimizing sustainable production of high-quality microalgae-derived extracellular vesicles through batch-refeed perfusion cultivation
- Open Access
- 15 May 2025
- Published by Elsevier in Process Biochemistry
- Vol. 155, 117-127
Bioactivity of autotrophic and mixotrophic Tetraselmis chuii (CCAP 66/21B) extracts against H2O2-mediated stress in A549 cells.
- 15 May 2025
- Published by Elsevier in Process Biochemistry
- Vol. 155, 117-127
Open AccessBioactivity of autotrophic and mixotrophic Tetraselmis chuii (CCAP 66/21B) extracts against H2O2-mediated stress in A549 cells.
- Open Access
- 23 April 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 187, 118081
Comparative effects of extracellular vesicles and liposomal nanocarriers on bleomycin-induced stress in A549 human adenocarcinoma cells
- 23 April 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 187, 118081
Open AccessComparative effects of extracellular vesicles and liposomal nanocarriers on bleomycin-induced stress in A549 human adenocarcinoma cells
- 27 January 2024
- Published by Elsevier in Food Bioscience
- Vol. 58
Comparative pigment and fatty acid profiling of marine species within the chlorophyte genus Tetraselmis
- 27 January 2024
- Published by Elsevier in Food Bioscience
- Vol. 58
Comparative pigment and fatty acid profiling of marine species within the chlorophyte genus Tetraselmis
- Open Access
- 1 December 2018
- Published by SAGE Publications in Human Gene Therapy Clinical Development
- Vol. 29 (4) , 188-197
Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice
Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated AAV2tYF-GRK1- RPGRco , to treat retinitis pigmentosa (RP) in patients with mutations in the retinitis pigmentosa GTPase regulator ( RPGR ) gene. The vector contains a codon-optimized human RPGR cDNA ( RPGRco ) driven by a photoreceptor-specific promoter (G protein–coupled receptor kinase 1, GRK1) and is packaged in an AAV2 capsid with three surface tyrosine residues changed to phenylalanine (AAV2tYF). We conducted a safety and potency study of this vector administered by subretinal a injection in the naturally occurring RPGR-deficient Rd9 mouse model. Sixty Rd9 mice (20 per group) received a subretinal injection in the right eye of vehicle (control) or AAV2tYF-GRK1- RPGRco at one of two dose levels (4 × 10 8 or 4 × 10 9 vg/eye) and were followed for 12 weeks after injection. Vector injections were well tolerated, with no systemic toxicity. There was a trend towards reduced electroretinography b -wave amplitudes in the high vector dose group that was not statistically significant. There were no clinically important changes in hematology or clinical chemistry parameters and no vector-related ocular changes in life or by histological examination. Dose-dependent RPGR protein expression, mainly in the inner segment of photoreceptors and the adjacent connecting cilium region, was observed in all vector-treated eyes examined. Sequence integrity of the codon-optimized RPGR was confirmed by sequencing of PCR-amplified DNA, or cDNA reverse transcribed from total RNA extracted from vector-treated retinal tissues, and by sequencing of RPGR protein obtained from transfected HEK 293 cells. These results support the use of rAAV2tYF-GRK1- RPGRco in clinical studies in patients with XLRP caused by RPGR mutations.
- 1 December 2018
- Published by SAGE Publications in Human Gene Therapy Clinical Development
- Vol. 29 (4) , 188-197
Open AccessToxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice
Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated AAV2tYF-GRK1- RPGRco , to treat retinitis pigmentosa (RP) in patients with mutations in the retinitis pigmentosa GTPase regulator ( RPGR ) gene. The vector contains a codon-optimized human RPGR cDNA ( RPGRco ) driven by a photoreceptor-specific promoter (G protein–coupled receptor kinase 1, GRK1) and is packaged in an AAV2 capsid with three surface tyrosine residues changed to phenylalanine (AAV2tYF). We conducted a safety and potency study of this vector administered by subretinal a injection in the naturally occurring RPGR-deficient Rd9 mouse model. Sixty Rd9 mice (20 per group) received a subretinal injection in the right eye of vehicle (control) or AAV2tYF-GRK1- RPGRco at one of two dose levels (4 × 10 8 or 4 × 10 9 vg/eye) and were followed for 12 weeks after injection. Vector injections were well tolerated, with no systemic toxicity. There was a trend towards reduced electroretinography b -wave amplitudes in the high vector dose group that was not statistically significant. There were no clinically important changes in hematology or clinical chemistry parameters and no vector-related ocular changes in life or by histological examination. Dose-dependent RPGR protein expression, mainly in the inner segment of photoreceptors and the adjacent connecting cilium region, was observed in all vector-treated eyes examined. Sequence integrity of the codon-optimized RPGR was confirmed by sequencing of PCR-amplified DNA, or cDNA reverse transcribed from total RNA extracted from vector-treated retinal tissues, and by sequencing of RPGR protein obtained from transfected HEK 293 cells. These results support the use of rAAV2tYF-GRK1- RPGRco in clinical studies in patients with XLRP caused by RPGR mutations.